Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SensorionXPAR:ALSEN +4,154.39%16 EV-to-OCF is -1.97 as of Sep. 17, 2026. GuruFocus rates XPAR:ALSEN with a GF Score™ of 16/100. The stock has 1 warning sign investors should review. Among 1,406 Biotechnology companies, Sensorion ranks worse than 54.48% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Sensorion's Enterprise Value is €53.86 Mil.
Sensorion's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €-27.28 Mil. Therefore, Sensorion's EV-to-OCF for today is -1.97.
The historical rank and industry rank for Sensorion's EV-to-OCF or its related term are showing as below:
XPAR:ALSEN'
s EV-to-OCF Range Over the Past 10 Years
Min: -16.07 Med: -0.97 Max: 1.55
Current: -2.61
During the past 13 years, the highest EV-to-OCF of Sensorion was 1.55. The lowest was -16.07. And the median was -0.97.
XPAR:ALSEN's EV-to-OCF is ranked worse than 54.48% of 1406
companies
in the Biotechnology industry
Industry Median: -3.335
vs XPAR:ALSEN: -2.61
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sensorion's share price for today is €9.70.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sensorion's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-4.898.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sensorion EV-to-OCF Related Terms
Sensorion EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Sensorion's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ALSEN vs VRTX, REGN, MRNA: EV-to-OCF Comparison
For the Biotechnology subindustry, Sensorion's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sensorion EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sensorion's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Sensorion's EV-to-OCF falls into.
Sensorion's current Enterprise Value is €53.86 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sensorion's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €-27.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sensorion (XPAR:ALSEN) has a EV-to-OCF of -1.97 as of Sep. 17, 2026. According to the industry distribution chart, Sensorion ranks #766 out of 1406 companies in the Biotechnology industry, placing it in the top 54.5%.
Is Sensorion's EV-to-OCF too high?
Sensorion's current EV-to-OCF is -1.97. Based on the distribution chart, Sensorion ranks #766 out of 1406 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Sensorion has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Sensorion's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sensorion ranks #766 out of 1406 companies for EV-to-OCF. This places Sensorion in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Sensorion's current EV-to-OCF is -1.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sensorion stock overvalued right now?
Sensorion (XPAR:ALSEN) has a current EV-to-OCF of -1.97. The current EV-to-OCF is -1.97. Sensorion's overall GF Score™ is 16/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Sensorion (XPAR:ALSEN), the current EV-to-OCF is -1.97 as of Sep. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sensorion SA is a France-based clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders. The SENS501 (OTOF-GT) targets deafness caused by mutations of the gene encoding for otoferlin and is currently developed in a Phase 1/2 clinical study, and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses. The company's pipeline programs are OTOF-GT (SENS-501), GJB2-GT, GJB2-GT, GJB2-GT, TREAT AND PREVENT, SENS-401 COCHLEAR, SENS-401 CIO, and SENS-401 SSNHL.
16GF Score
Get the complete analysis for XPAR:ALSEN
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALSEN has been successfully added to your 
